Fangsheng pharmaceutical: RMB 176 million to acquire 100% equity of tengwangge pharmaceutical

2022 Informatization of China's Rehabilitation Industry

The rehabilitation industry caught the attention of the Chinese government again in 2021, and the industry entered a phase of accelerated development. The rehabilitation industry will first supplement medical resources and continue to explore a rehabilitation model that suits China's actual conditions. Under this context, EqualOcean Intelligence, together with Neusoft Group, released the 2022 Research Report On the Informatization of China's Rehabilitation Industry.

15 Companies to Watch in September 2022- Healthcare

Editor's note: We at EqualOcean tracked the major funding rounds or industry events that took place in China's healthcare space in September 2022. And the following is a list of deals that we have selected for you, based on a number of criteria, including the funding amount, the financial backers, and the segments in which the startups operate.

Insight Lifetech Completes Series D+ Equity Round

Insight Lifetech, a high-tech company dedicated to providing innovative solutions for cardiovascular disease precision intervention, will continue to provide more innovative products and services and provide changes to precision diagnosis and treatment of cardiovascular diseases.

Animal Vaccine Developer Vbiosci Nets Hundreds of Mns of CNY in Series B Round

Vbiosci's pipeline covers poultry, livestock and pets.

FCC Proposes Even More Stringent Restrictions on China

Acting FCC Chairwoman Jessica Rosenworcel said the new measures would "exclude untrustworthy devices and suppliers from the communication network."